Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Impact of cardiovascular outcomes on the development and approval of medications for the treatment of diabetes mellitus.

Joffe HV, Parks MH, Temple R.

Rev Endocr Metab Disord. 2010 Mar;11(1):21-30. doi: 10.1007/s11154-010-9130-8. Review.

PMID:
20195772
2.

Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus.

Azim S, Baker WL, White WB.

Curr Cardiol Rep. 2014 Nov;16(11):541. doi: 10.1007/s11886-014-0541-0. Review.

PMID:
25303895
3.

Assessing the cardiovascular safety of diabetes therapies.

Goldfine AB.

N Engl J Med. 2008 Sep 11;359(11):1092-5. doi: 10.1056/NEJMp0805758. No abstract available.

5.

Is Hemoglobin A1c the Right Outcome for Studies of Diabetes?

Lipska KJ, Krumholz HM.

JAMA. 2017 Mar 14;317(10):1017-1018. doi: 10.1001/jama.2017.0029. No abstract available.

6.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

7.

Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies.

Chawla AJ, Mytelka DS, McBride SD, Nellesen D, Elkins BR, Ball DE, Kalsekar A, Towse A, Garrison LP.

Pharmacoepidemiol Drug Saf. 2014 Mar;23(3):268-77. Epub 2014 Jan 14.

8.

What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?

Lovre D, Htun W, Carrion C, Fonseca VA.

Curr Diab Rep. 2016 Oct;16(10):94. doi: 10.1007/s11892-016-0788-5. Review.

PMID:
27541296
9.

Characterization of cardiovascular outcomes in a type 2 diabetes glucose supply and insulin demand model.

Monte SV, Schentag JJ, Adelman MH, Paladino JA.

J Diabetes Sci Technol. 2010 Mar 1;4(2):382-90.

10.

Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.

Thrasher J.

Am J Med. 2017 Jun;130(6S):S4-S17. doi: 10.1016/j.amjmed.2017.04.004. Review.

11.

Rosiglitazone and the FDA.

Joffe HV, Parks MH, Meyer RJ, Jenkins JK, Temple R.

N Engl J Med. 2007 Oct 25;357(17):1775-6; author reply 1777. Epub 2007 Aug 29. No abstract available.

12.

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

Nissen SE, Wolski K, Topol EJ.

JAMA. 2005 Nov 23;294(20):2581-6. Epub 2005 Oct 20.

PMID:
16239637
13.

Perspectives on Some Controversies in Cardiovascular Disease Risk Assessment in the Pharmaceutical Development of Glucose-Lowering Medications.

Hoogwerf BJ, Manner DH, Fu H, Moscarelli E, Gaydos BL, Heine RJ.

Diabetes Care. 2016 Aug;39 Suppl 2:S219-27. doi: 10.2337/dcS15-3025. Review.

PMID:
27440836
15.

Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.

Thrasher J.

Am J Cardiol. 2017 Jul 1;120(1S):S4-S16. doi: 10.1016/j.amjcard.2017.05.009. Epub 2017 May 30. Review.

16.

Achieving better outcomes in pregnancies complicated by type 1 and type 2 diabetes mellitus.

Kinsley B.

Clin Ther. 2007;29 Suppl D:S153-60. doi: 10.1016/j.clinthera.2007.12.015. Review.

PMID:
18191067
17.

Cardiovascular risks and benefits with oral drugs for Type 2 diabetes mellitus.

Weidman-Evans E, Metz SM, Evans JD.

Expert Rev Clin Pharmacol. 2014 Mar;7(2):225-33. doi: 10.1586/17512433.2014.885836. Epub 2014 Feb 4. Review.

PMID:
24490745
18.

Regulatory watch: FDA issues guidance for cardiovascular risk assessment of novel antidiabetic agents.

[No authors listed]

Nat Rev Drug Discov. 2009 Feb;8(2):99. doi: 10.1038/nrd2823. No abstract available.

PMID:
19180100
19.

Association of the FDA Amendment Act with trial registration, publication, and outcome reporting.

Phillips AT, Desai NR, Krumholz HM, Zou CX, Miller JE, Ross JS.

Trials. 2017 Jul 18;18(1):333. doi: 10.1186/s13063-017-2068-3. Review.

20.

Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.

Lo C, Jun M, Badve SV, Pilmore H, White SL, Hawley C, Cass A, Perkovic V, Zoungas S.

Cochrane Database Syst Rev. 2017 Feb 27;2:CD009966. doi: 10.1002/14651858.CD009966.pub2. Review.

PMID:
28238223

Supplemental Content

Support Center